Ones To Watch News
Refine Search
Biotechnology
Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, has emerged from stealth. 17 October 2023
Pharmaceutical
Danish company Novo Nordisk has agreed to acquire ocedurenone - a drug in development for uncontrolled hypertension with potential application in cardiovascular and kidney disease - from Singapore biotech KBP Biosciences for up to $1.3 billion. 16 October 2023
Biotechnology
ZQ Capital Management has made an offer for UK-based Allergy Therapeutics, as required by takeover rules. 16 October 2023
Biotechnology
PHIOGEN Pharmaceuticals, an innovative biotech start-up housed in the Texas Medical Center Innovation Hub and pioneering next-generation bacteriophage-based therapeutics, has appointed Dr Mayukh Das as chief operations officer (COO). 16 October 2023
Biotechnology
Interim Phase II data from the Phase II/III Orbit study demonstrate setrusumab resulted in 67% reduction in annualized fracture rate, as well as continuous and meaningful improvements in bone mineral density (BMD) in patients with osteogenesis imperfecta (OI). 16 October 2023
Biotechnology
The Lonza subsidiary Synaffix, which is focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has entered a licensing deal with SOTIO Biotech. 16 October 2023
Biotechnology
Swiss biotech firm MoonLake Immunotherapeutics saw its US traded shares rise pre-market, after it announced positive 24-week top-line results from its global Phase II MIRA trial. 16 October 2023
Pharmaceutical
USA-based CNS disease specialist Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). 13 October 2023
Biotechnology
China-headquartered independent biotech MediLink Therapeutics has entered into a strategic research collaboration and worldwide license agreement with Germany’s BioNTech on the development of a next-generation antibody-drug conjugate (ADC) candidate against human epidermal growth factor receptor 3 (HER3). 13 October 2023
Biotechnology
China’s CARsgen Therapeutics has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with its CAR-GPC3 T-cell therapy. 12 October 2023
Biotechnology
Israel-based cancer and rare diseases drug developer BioLineRx today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia, with the news sending BioLineRx’ shares up 6.7% to $1.60. 12 October 2023
Biotechnology
Swedish biotech Promore Pharma will soon run out of money, and has begun liquidation proceedings, the company announced. 12 October 2023
Pharmaceutical
Swedish company Egetis Therapeutics has raised around $16 million in a private share placement led by US healthcare investor Frazier Life Sciences. 11 October 2023
Biotechnology
UK clinical-stage biotech PureTech Health has presented new clinical data supporting the differentiated profile of LYT-100 (deupirfenidone) at the CHEST Annual Meeting in Honolulu, Hawaii. 11 October 2023
Biotechnology
Danish biotech MinervaX, a privately held firm working on a novel, prophylactic vaccine against Group B Streptococcus (GBS), has raised $57 million from a range of new and existing sources of finance. 11 October 2023
Biotechnology
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences closed 26% lower after Tuesday’s trading. 11 October 2023
Biotechnology
With the aim of advancing its fibrosis-focused pipeline, Belgian biotech Agomab Therapeutics today announced the closing of a $100 million (94.9 million euros) Series C financing. 11 October 2023
Biotechnology
Experienced neuroscience drug development executive Robert Lenz has joined Neumora Therapeutics. 10 October 2023
Pharmaceutical
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
Biotechnology
US clinical-stage biotech Akero Therapeutics saw its shares slump 59% to $48.44, after it released new data Phase IIb data on its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to non-alcoholic steatohepatitis (NASH), joining a string of companies failing in their attempts in this therapy area. 10 October 2023
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze